Phase 2Completed
Phase 2 Study Comparing 99mTc-EC-DG SPECT/CT With 18F FDG PET/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
A Multicenter Phase 2 Study Comparing 99m Tc EC-DG SPECT/CT With 18F FDG PET/CT in the Evaluation of Patients With Non-small Cell Lung Cancer (NSCLC)
- Sponsor
- Cell>Point LLC (Industry)
- Enrollment
- 22 enrolled
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose); 18 F fluorodeoxyglucose
- Ages
- adults, older adults
- Registry
- NCT00865319
Full record on ClinicalTrials.gov
From the registry
This is a multiple-center Phase 2 study designed to expand the patient safety and clinical information using 99m Tc-Ec-DG with Spect/CT imaging, to develop procedures and methods for evaluation of the imaging studies, to determine comparability of diagnostic information between SPECT and SPECT/CT imaging and to to compare the safety and efficacy of 99m Tc-EC-DG SPECT/CT with 18F-FDG PET/CT in imaging patients with biopsy confirmed diagnosis of Non-small Cell Lung Cancer.
Primary outcomes
- Safety: Through adverse event collection
History
Last registry update
Study completion
Primary completion
Started
Registered